Publication
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
Fabio Conforti, Jacopo Canzian, Benedetta Tinterri, Laura Pala, Marzia Bendoni, Marzia Locatelli, Tommaso De Pas, Aldo Caltavituro, James C Dickerson, Carmen Criscitiello, Francesco Schettini, Aleix Prat, Javier Cortes, Giuseppe Viale, Martine Piccart, Richard Gelber
- Source
- PubMed
- Retrieved
- Oct 2, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261002-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Over the past two decades, targeted anti-HER2 therapies have transformed management of HER2-positive early breast cancer (HER2 + eBC), enabling chemotherapy de-escalation without compromising efficacy. This review assesses the rationale for incorporating carboplatin into (neo)adjuvant regimens and…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available